These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 15578159

  • 1. Strontium ranelate: a novel mode of action optimizing bone formation and resorption.
    Marie PJ.
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S7-10. PubMed ID: 15578159
    [Abstract] [Full Text] [Related]

  • 2. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.
    Marie PJ.
    Osteoporos Int; 2003 Jan; 14 Suppl 3():S9-12. PubMed ID: 12730801
    [Abstract] [Full Text] [Related]

  • 3. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
    Marie PJ.
    Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
    [Abstract] [Full Text] [Related]

  • 4. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ.
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [Abstract] [Full Text] [Related]

  • 5. Strontium ranelate in osteoporosis.
    Reginster JY.
    Curr Pharm Des; 2002 Jun; 8(21):1907-16. PubMed ID: 12171530
    [Abstract] [Full Text] [Related]

  • 6. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
    Dimai HP.
    Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Strontium ranelate: a novel mode of action leading to renewed bone quality.
    Ammann P.
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S11-5. PubMed ID: 15578157
    [Abstract] [Full Text] [Related]

  • 9. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E, Chabadel A, Saltel F, Jurdic P.
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate.
    Manette C, Collette J, Sarlet N, Tancredi A, Zegels B, Reginster JY.
    Curr Med Chem; 2006 Jan; 13(13):1585-90. PubMed ID: 16787205
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
    Delmas PD.
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.
    N Engl J Med; 2004 Jan 29; 350(5):459-68. PubMed ID: 14749454
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Strontium ranelate: a physiological approach for an improved bone quality.
    Ammann P.
    Bone; 2006 Feb 29; 38(2 Suppl 1):15-8. PubMed ID: 16455318
    [Abstract] [Full Text] [Related]

  • 18. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S, Vai S.
    Bone; 2006 Feb 29; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength.
    Fonseca JE.
    Rheumatology (Oxford); 2008 Jul 29; 47 Suppl 4(Suppl 4):iv17-19. PubMed ID: 18556645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.